Candel Therapeutics, Inc. (CADL)
Automate Your Wheel Strategy on CADL
With Tiblio's Option Bot, you can configure your own wheel strategy including CADL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CADL
- Rev/Share 0.0182
- Book/Share 1.4596
- PB 3.9531
- Debt/Equity 0.0778
- CurrentRatio 8.2472
- ROIC -0.4655
- MktCap 316778095.0
- FreeCF/Share -0.6146
- PFCF -9.3894
- PE -27.5666
- Debt/Assets 0.0666
- DivYield 0
- ROE -0.1476
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CADL | Stephens | -- | Overweight | -- | $15 | Oct. 28, 2025 |
| Downgrade | CADL | BofA Securities | Buy | Neutral | -- | $7 | Sept. 3, 2025 |
| Resumed | CADL | H.C. Wainwright | -- | Buy | -- | $23 | June 30, 2025 |
| Initiation | CADL | Citigroup | -- | Buy | -- | $25 | Feb. 20, 2025 |
| Initiation | CADL | Canaccord Genuity | -- | Buy | -- | $20 | Feb. 19, 2025 |
| Initiation | CADL | BofA Securities | -- | Buy | -- | $15 | Feb. 7, 2025 |
News
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership.
Read More
Candel Therapeutics appoints cancer immunology expert to research advisory board
Published: March 18, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Read More
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
Published: February 28, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Read More
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects.
Read More
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC.
Read More
About Candel Therapeutics, Inc. (CADL)
- IPO Date 2021-07-27
- Website https://www.candeltx.com
- Industry Biotechnology
- CEO Paul-Peter Tak
- Employees 38